A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Lucid Diagnostics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 29,301 shares of LUCD stock, worth $26,077. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,301
Previous 29,639 1.14%
Holding current value
$26,077
Previous $41,000 43.9%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$0.81 - $1.52 $273 - $513
-338 Reduced 1.14%
29,301 $23,000
Q4 2023

Feb 14, 2024

SELL
$1.16 - $1.54 $7,813 - $10,373
-6,736 Reduced 18.52%
29,639 $41,000
Q3 2023

Nov 14, 2023

SELL
$1.17 - $1.65 $30,579 - $43,124
-26,136 Reduced 41.81%
36,375 $42,000
Q2 2023

Aug 14, 2023

BUY
$1.28 - $1.78 $80,014 - $111,269
62,511 New
62,511 $86,000
Q3 2022

Nov 14, 2022

BUY
$1.68 - $3.45 $7,570 - $15,545
4,506 Added 14.62%
35,333 $54,000

Others Institutions Holding LUCD

About Lucid Diagnostics Inc.


  • Ticker LUCD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 38,568,500
  • Market Cap $34.3M
  • Description
  • Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...
More about LUCD
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.